中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
13期
1974-1976
,共3页
乌司他丁%哮喘%C反应蛋白质%一氧化氮
烏司他丁%哮喘%C反應蛋白質%一氧化氮
오사타정%효천%C반응단백질%일양화담
Ulinastatin%Asthma%C-reactive protein%Nitric oxide
目的 探讨乌司他丁对支气管哮喘患者血清CRP和呼出气一氧化氮(FeNO)的影响.方法 98例支气管哮喘患者按照数字表法随机分为对照组49例和观察组49例,对照组采用常规治疗,观察组在常规治疗的基础上加用乌司他丁治疗.治疗前后测定肺功能、哮喘症状评分、血清CRP和FeNO.结果 两组治疗后FEV1占预计值百分率和PEF占预计值百分率均有明显升高(t=4.720、8.112、3.724、6.723,均P＜0.05),与对照组比较,观察组治疗后升高更明显(t=3.102、4.002,均P＜0.05).两组治疗后哮喘症状评分均有明显降低(t=2.190、6.021,均P＜0.05),与对照组比较,观察组治疗后降低更明显(t=2.620,P＜0.05).两组治疗后FeNO和CRP均明显降低(t=9.124、13.076、5.772、7.064,均P＜0.01),与对照组比较,观察组治疗后降低更明显(t =3.060、5.401,均P＜0.05).结论 乌司他丁可以明显降低支气管哮喘患者血清CRP和FeNO.
目的 探討烏司他丁對支氣管哮喘患者血清CRP和呼齣氣一氧化氮(FeNO)的影響.方法 98例支氣管哮喘患者按照數字錶法隨機分為對照組49例和觀察組49例,對照組採用常規治療,觀察組在常規治療的基礎上加用烏司他丁治療.治療前後測定肺功能、哮喘癥狀評分、血清CRP和FeNO.結果 兩組治療後FEV1佔預計值百分率和PEF佔預計值百分率均有明顯升高(t=4.720、8.112、3.724、6.723,均P＜0.05),與對照組比較,觀察組治療後升高更明顯(t=3.102、4.002,均P＜0.05).兩組治療後哮喘癥狀評分均有明顯降低(t=2.190、6.021,均P＜0.05),與對照組比較,觀察組治療後降低更明顯(t=2.620,P＜0.05).兩組治療後FeNO和CRP均明顯降低(t=9.124、13.076、5.772、7.064,均P＜0.01),與對照組比較,觀察組治療後降低更明顯(t =3.060、5.401,均P＜0.05).結論 烏司他丁可以明顯降低支氣管哮喘患者血清CRP和FeNO.
목적 탐토오사타정대지기관효천환자혈청CRP화호출기일양화담(FeNO)적영향.방법 98례지기관효천환자안조수자표법수궤분위대조조49례화관찰조49례,대조조채용상규치료,관찰조재상규치료적기출상가용오사타정치료.치료전후측정폐공능、효천증상평분、혈청CRP화FeNO.결과 량조치료후FEV1점예계치백분솔화PEF점예계치백분솔균유명현승고(t=4.720、8.112、3.724、6.723,균P＜0.05),여대조조비교,관찰조치료후승고경명현(t=3.102、4.002,균P＜0.05).량조치료후효천증상평분균유명현강저(t=2.190、6.021,균P＜0.05),여대조조비교,관찰조치료후강저경명현(t=2.620,P＜0.05).량조치료후FeNO화CRP균명현강저(t=9.124、13.076、5.772、7.064,균P＜0.01),여대조조비교,관찰조치료후강저경명현(t =3.060、5.401,균P＜0.05).결론 오사타정가이명현강저지기관효천환자혈청CRP화FeNO.
Objective To study the effect of ulinastatin on serum C-reactive protein (CRP) and exhaled nitric oxide(FeNO) in patients with bronchial asthma.Methods 98 patients with bronchial asthma were randomly divided into the control group (n =49 cases) and the observation group (n =49 cases).The patients in the control group were treated through the conventional treatment,while the patients in the observation group were treated through the conventional treatment plus ulinastatin.Pulmonary function,asthma symptom scores,serum CRP and FeNO were measured before and after treatment.Results FEV1％ and predicted PEF values after treatment were significantly increased (t =4.720,8.112,3.724,6.723,all P ＜ 0.05).Compared with the control group,the observation group after treatment increased more significantly (t =3.102,4.002,all P ＜ 0.05).After the treatment,the asthma symptom scores were significantly decreased (t =2.190,6.021,all P ＜ 0.05).Compared with the control group,the asthma symptom scores of the observation group significantly decreased (t =2.620,P ＜ 0.05).After treatment,FeNO and CRP were significantly decreased (t =9.124,13.076,5.772,7.064,all P ＜ 0.01).Compared with the control group,FeNO and CRP of the observation group significantly decreased (t =3.060,5.401,all P ＜ 0.05).Conclusion Ulinastatin can significantly decrease serum CRP and FeNO in patients with bronchial asthma.
